{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:42:58Z","timestamp":1777934578183,"version":"3.51.4"},"reference-count":18,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T00:00:00Z","timestamp":1671408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>We aimed to compare the safety of lenvatinib as first-line treatment for unresectable hepatocellular carcinoma (HCC) in patients with Child-Pugh A (CP-A) and Child-Pugh B (CP-B) and to determine the adverse events (AEs) that cause dose reduction\/interruption of treatment in patients with CP-B.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Sixty-six patients with lenvatinib as a first-line treatment for HCC at Ogaki Municipal Hospital (Ogaki, Japan) between April 2018 and January 2022 were retrospectively evaluated. We analyzed the treatment duration, AEs, and reasons for dose reduction\/interruption associated with lenvatinib treatment in patients with CP-A and CP-B HCC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The CP-B group had significantly more cases of grade \u2265 2 fatigue and anorexia than the CP-A group ( p\u2009\u2009=\u2009\u20090.045 and p\u2009\u2009=\u2009\u20090.042, respectively). Regarding AEs that caused dose reduction\/interruption of treatment, the CP-A group had significantly more cases of proteinuria than the CP-B group ( p\u2009\u2009=\u2009\u20090.015), whereas the CP-B group had significantly more cases of hand-foot syndrome (HFS) than the CP-A group ( p\u2009\u2009=\u2009\u20090.013).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Patients with CP-B have greater difficulty than patients with CP-A in continuing treatment with repeated dose reductions\/interruption of treatment due to intolerable grade \u2265 2 AEs (fatigue and anorexia). HFS is more likely to cause dose reduction\/interruption of treatment in CP-B than in CP-A unresectable HCC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552221145475","type":"journal-article","created":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T02:27:41Z","timestamp":1671503261000},"page":"1637-1645","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Analysis of adverse events leading to dose reduction\/interruption of lenvatinib treatment in patients with Child-Pugh B unresectable hepatocellular carcinoma"],"prefix":"10.1177","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6009-5772","authenticated-orcid":false,"given":"Michio","family":"Kimura","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Ogaki Municipal Hospital, Ogaki-shi, Gifu, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Asano","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Ogaki Municipal Hospital, Ogaki-shi, Gifu, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3422-3072","authenticated-orcid":false,"given":"Eiseki","family":"Usami","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Ogaki Municipal Hospital, Ogaki-shi, Gifu, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitomi","family":"Teramachi","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Pharmacy, Gifu Pharmaceutical University, Gifu-shi, Gifu, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoaki","family":"Yoshimura","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Ogaki Municipal Hospital, Ogaki-shi, Gifu, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2022,12,19]]},"reference":[{"key":"bibr1-10781552221145475","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915745"},{"key":"bibr2-10781552221145475","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/638747"},{"key":"bibr3-10781552221145475","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.13710"},{"key":"bibr4-10781552221145475","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11111769"},{"key":"bibr5-10781552221145475","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0231828"},{"key":"bibr6-10781552221145475","doi-asserted-by":"publisher","DOI":"10.1177\/1758835920922051"},{"key":"bibr7-10781552221145475","doi-asserted-by":"publisher","DOI":"10.2147\/CEG.S256691"},{"key":"bibr8-10781552221145475","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2014.10.006"},{"key":"bibr9-10781552221145475","unstructured":"US Department of Health and Human Services: common terminology criteria for adverse events (CTCAE) version 5.0. United States, National Cancer Institute, https:\/\/ctep.Cancer.Gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5\u00d711.pdf (2017)."},{"key":"bibr10-10781552221145475","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2012.244"},{"key":"bibr11-10781552221145475","doi-asserted-by":"publisher","DOI":"10.1002\/jhbp.821"},{"key":"bibr12-10781552221145475","doi-asserted-by":"publisher","DOI":"10.1016\/S1542-3565(05)00017-0"},{"key":"bibr13-10781552221145475","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.12954"},{"key":"bibr14-10781552221145475","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.12194"},{"key":"bibr15-10781552221145475","doi-asserted-by":"publisher","DOI":"10.1080\/01635581.2019.1597905"},{"key":"bibr16-10781552221145475","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12010049"},{"key":"bibr17-10781552221145475","doi-asserted-by":"publisher","DOI":"10.21873\/invivo.11452"},{"key":"bibr18-10781552221145475","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.13597"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552221145475","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552221145475","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552221145475","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:27:44Z","timestamp":1777688864000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552221145475"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,19]]},"references-count":18,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["10.1177\/10781552221145475"],"URL":"https:\/\/doi.org\/10.1177\/10781552221145475","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,19]]}}}